Search Results - "Mizuno‐Yasuhira, Akiko"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data by Inatani, Shoko, MizunoYasuhira, Akiko, Kamiya, Makoto, Nishino, Izumi, Sabia, Helene D., Endo, Hiromi

    Published in Biopharmaceutics & drug disposition (01-05-2021)
    “…THY1773 is a novel arginine vasopressin 1B (V1B) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder…”
    Get full text
    Journal Article
  2. 2

    Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia by Konno, Yoshihiro, Kamigaso, Shunsuke, Toki, Hidetoh, Terasaka, Shuichi, Hikichi, Hirohiko, Endo, Hiromi, Yamaguchi, Jun‐Ichi, MizunoYasuhira, Akiko

    Published in Pharmacology research & perspectives (01-04-2024)
    “…We investigated the metabolism and disposition of vornorexant, a novel dual orexin receptor antagonist, in rats and dogs, and clarified in vitro metabolite…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Prediction of a clinically effective dose of THY1773, a novel V 1B receptor antagonist, based on preclinical data by Inatani, Shoko, Mizuno-Yasuhira, Akiko, Kamiya, Makoto, Nishino, Izumi, Sabia, Helene D, Endo, Hiromi

    Published in Biopharmaceutics & drug disposition (01-05-2021)
    “…THY1773 is a novel arginine vasopressin 1B (V ) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder…”
    Get full text
    Journal Article
  5. 5

    Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model by Zhang, Kai, Toki, Hidetoh, Fujita, Yuko, Ma, Min, Chang, Lijia, Qu, Youge, Harada, Shingo, Nemoto, Tetsuhiro, Mizuno-Yasuhira, Akiko, Yamaguchi, Jun-ichi, Chaki, Shigeyuki, Hashimoto, Kenji

    Published in Psychopharmacology (01-11-2018)
    “…Rationale ( R,S )-ketamine, an N -methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans by Miyata, Atsunori, Hasegawa, Masatoshi, Hachiuma, Kenji, Mori, Haruyuki, Horiuchi, Nobuko, Mizuno-Yasuhira, Akiko, Chino, Yukihiro, Jingu, Shigeji, Sakai, Soichi, Samukawa, Yoshishige, Nakai, Yasuhiro, Yamaguchi, Jun-ichi

    Published in Xenobiotica (01-04-2017)
    “…1. To understand the clearance mechanism of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, we investigated its human metabolite profile…”
    Get full text
    Journal Article
  8. 8

    A sensitive and selective method for the quantitative analysis of miglitol in rat plasma using unique solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry by Mizuno-Yasuhira, Akiko, Kinoshita, Kohnosuke, Jingu, Shigeji, Yamaguchi, Jun-ichi

    Published in Biomedical chromatography (01-10-2014)
    “…ABSTRACT A sensitive, selective and robust liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method was developed for the quantification of miglitol in…”
    Get full text
    Journal Article
  9. 9
  10. 10

    (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice by Yamaguchi, Jun-Ichi, Toki, Hidetoh, Qu, Youge, Yang, Chun, Koike, Hiroyuki, Hashimoto, Kenji, Mizuno-Yasuhira, Akiko, Chaki, Shigeyuki

    Published in Neuropsychopharmacology (New York, N.Y.) (01-08-2018)
    “…(R,S)-Ketamine has rapid and sustained antidepressant effects in depressed patients. Although the metabolism of (R,S)-ketamine to (2 R,6 R)-hydroxynorketamine…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals? by Takano, Hiroki, Mizuno-Yasuhira, Akiko, Yamaguchi, Jun-ichi, Endo, Hiromi

    Published in Xenobiotica (03-07-2022)
    “…1. TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, is reportedly excreted predominantly through urinary excretion in an unchanged…”
    Get full text
    Journal Article
  13. 13

    No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model by Chang, Lijia, Toki, Hidetoh, Qu, Youge, Fujita, Yuko, Mizuno-Yasuhira, Akiko, Yamaguchi, Jun-Ichi, Chaki, Shigeyuki, Hashimoto, Kenji

    “…Although previous reports suggest sex-specific differences in the antidepressant actions of (R,S)-ketamine, these differences in the antidepressant actions of…”
    Get full text
    Journal Article
  14. 14

    Development and validation of a liquid chromatography–tandem mass spectrometric method for the quantification of 5-thio-d-glucose in rat and human plasma by Mizuno-Yasuhira, Akiko, Jingu, Shigeji, Okuyama, Shigeru

    “…► An LC–MS/MS method for the analysis of 5-thio-d-glucose in plasma was developed. ► The validated quantitation range was from 10 to 3000ng/mL. ► This is the…”
    Get full text
    Journal Article